Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study

  • Yan Hong
  • Pengxian Shi
  • Xia Liu
  • Liu Yang
  • Kang Li
  • Feng Xu
  • Shaoshan Liang
  • Zhengzhao Liu
  • Haitao Zhang
  • Yinghua ChenEmail author
  • Weixin HuEmail author
Original Article



To retrospectively investigate the clinical and histological features and outcomes of ANCA-associated glomerulonephritis (AAGN) with different ANCA serotypes.


A total of 467 AAGN patients were divided into MPO-AAGN (MPO) and PR3-AAGN (PR3) groups according to ANCA serotype. Clinical and histological features and renal outcomes were compared.


In this study, 429 (91.9%) patients tested positive for MPO-ANCA, and 38 (8.1%) for PR3-ANCA. The median age at diagnosis (P = 0.017) and proportion of females (P = 0.003) were higher in the MPO group. Joint (P < 0.001), ENT (P = 0.000), skin (P = 0.007), and eye (P = 0.014) involvements were more common in the PR3 group. Compared with that in the PR3-group, a higher proportion of patients in the MPO group had microscopic polyangiitis (P = 0.000), and a lower proportion of exhibited granulomatosis with polyangiitis (P = 0.000). Patients in the MPO group also exhibited lower BVAS scores (P = 0.003) and higher serum albumin levels (P = 0.009). Histologically, a lower proportion of MPO patients had crescentic glomerulonephritis (P = 0.028) and acute tubule-interstitial lesion scores (P = 0.007), but a higher proportion of these patients exhibited mixed class glomerulonephritis (P = 0.032) than in the PR3 group. The relapse rate was lower (P = 0.020), and the 5-year relapse-free survival rate (P = 0.003) was higher in the MPO group than in the PR3 group. However, the 5-year renal survival rates (P = 0.106) were not significantly different.


MPO-ANCA was predominant in Chinese patients with ANCA-associated vasculitis and renal disease. The epidemiological characteristics, extra-renal involvement, and histopathological classes and outcomes were different between MPO-positive and PR3-positive patients, implying that they might be two different disease entities.


Antineutrophil cytoplasmic antibody Glomerulonephritis Myeloperoxidase Proteinase 3 


Funding information

This study was supported by the Natural Science Foundation of China (81770701) and the National Key Research and Development Program of China (2016YFC0904103).

Compliance with ethical standards

Ethical approval of the study was obtained from the ethics committee of Nanjing Jinling Hospital, Nanjing, China. This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All patients gave their informed consent prior to their inclusion in the study.




  1. 1.
    Kallenberg CG (2010) Pathophysiology of ANCA-associated small vessel vasculitis. Curr Rheumatol Rep 12:399–405CrossRefGoogle Scholar
  2. 2.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11CrossRefGoogle Scholar
  3. 3.
    Cohen Tervaert JW, Damoiseaux J (2012) Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up? Clin Rev Allergy Immunol 43:211–219CrossRefGoogle Scholar
  4. 4.
    Chen M, Yu F, Zhang Y, Zou WZ, Zhao MH, Wang HY (2005) Characteristics of Chinese patients with Wegener’s granulomatosis with antimyeloperoxidase autoantibodies. Kidney Int 68:2225–2229CrossRefGoogle Scholar
  5. 5.
    Hilhorst M, van Paassen P, Tervaert JW, Limburg Renal Registry (2015) Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol 26:2314–2327CrossRefGoogle Scholar
  6. 6.
    Chen M, Yu F, Zhang Y, Zhao MH (2005) Clinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single center. Postgrad Med J 81:723–727CrossRefGoogle Scholar
  7. 7.
    Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, Neumann I, Noël LH, Pusey CD, Waldherr R, Bruijn JA, Bajema IM (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21:1628–1636CrossRefGoogle Scholar
  8. 8.
    Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594CrossRefGoogle Scholar
  9. 9.
    Hu W, Liu C, Xie H, Chen H, Liu Z, Li L (2008) Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 23:1307–1312CrossRefGoogle Scholar
  10. 10.
    Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, Chen J, Lin H, Liu F, He Y, He Y, Miao L, Chen N, Li Y, Gu Y, Shi W, Hu W, Liu Z, Bao H, Zeng C, Zhou M (2015) Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162:18–26CrossRefGoogle Scholar
  11. 11.
    Hu W, Liu Z, Ji D, Xie H, Gong D, Li L (2006) Staphylococcal protein A immunoadsorption for Goodpasture's syndrome in four Chinese patients. J Nephrol 19:312–317Google Scholar
  12. 12.
    Chen Y, Yang L, Li K, Liu Z, Gong D, Zhang H, Liu Z, Hu W (2016) Double filtration plasmapheresis in the treatment of antineutrophil cytoplasmic autoantibody associated vasculitis with severe renal failure: a preliminary study of 15 patients. Ther Apher Dial 20:183–188CrossRefGoogle Scholar
  13. 13.
    Ono N, Niiro H, Ueda A, Sawabe T, Nishizaka H, Furugo I, Yoshizawa S, Yoshizawa S, Tsukamoto H, Kiyohara C, Tada Y, Horiuchi T (2015) Characteristics of MPO-ANCA-positive granulomatosis with polyangiitis: a retrospective multi-center study in Japan. Rheumatol Int 35:555–559CrossRefGoogle Scholar
  14. 14.
    Mohammad AJ, Segelmark M (2014) A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol 41:1366–1373CrossRefGoogle Scholar
  15. 15.
    Liu LJ, Chen M, Yu F, Zhao MH, Wang HY (2008) Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology (Oxford) 47:708–712CrossRefGoogle Scholar
  16. 16.
    Chen M, Yu F, Wang SX, Zou WZ, Zhang Y, Zhao MH, Wang HY (2007) Renal histology in Chinese patients with anti-myeloperoxidase autoantibody-positive Wegener’s granulomatosis. Nephrol Dial Transplant 22:139–145CrossRefGoogle Scholar
  17. 17.
    Watts RA, Gonzalez-Gay MA, Lane SE, Garcia-Porrua C, Bentham G, Scott DG (2001) Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 60:170–172CrossRefGoogle Scholar
  18. 18.
    Ntatsaki E, Watts RA, Scott DG (2010) Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin N Am 36:447–461CrossRefGoogle Scholar
  19. 19.
    Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M (2007) Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg–Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 46:1329–1337CrossRefGoogle Scholar
  20. 20.
    O’Donnell JL, Stevanovic VR, Frampton C, Stamp LK, Chapman PT (2007) Wegener’s granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient. Intern Med J 37:242–246CrossRefGoogle Scholar
  21. 21.
    Gibson A, Stamp LK, Chapman PT, O'Donnell JL (2006) The epidemiology of Wegener’s granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology (Oxford) 45:624–628CrossRefGoogle Scholar
  22. 22.
    Koldingsnes W, Nossent H (2000) Epidemiology of Wegener’s granulomatosis in northern Norway. Arthritis Rheum 43:2481–2487CrossRefGoogle Scholar
  23. 23.
    Ormerod AS, Cook MC (2008) Epidemiology of primary systemic vasculitis in the Australian Capital Territory and South-Eastern New South Wales. Intern Med J 38:816–823CrossRefGoogle Scholar
  24. 24.
    Slot MC, Sokolowska MG, Savelkouls KG, Janssen RG, Damoiseaux JG, Tervaert JW (2008) Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis. Clin Immunol 128:39–45CrossRefGoogle Scholar
  25. 25.
    Jagiello P, Aries P, Arning L, Wagenleiter SE, Csernok E, Hellmich B, Gross WL, Epplen JT (2005) The PTPN22 620W allele is a risk factor for Wegener’s granulomatosis. Arthritis Rheum 52:4039–4043CrossRefGoogle Scholar
  26. 26.
    Stassen PM, Cohen-Tervaert JW, Lems SP, Hepkema BG, Kallenberg CG, Stegeman CA (2009) HLA-DR4, DR13(6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener’s granulomatosis. Rheumatology (Oxford) 48:622–625CrossRefGoogle Scholar
  27. 27.
    Solans-Laqué R, Fraile G, Rodriguez-Carballeira M, Caminal L, Castillo MJ, Martínez-Valle F, Sáez L, Rios JJ, Solanich X, Oristrell J, Pasquau F, Fonseca E, Zamora M, Callejas JL, Frutos B, Abdilla M, Fanlo P, García-Sánchez I, López-Dupla M, Sopeña B, Pérez-Iglesias A, Bosch JA, Spanish Registry of systemic vasculitis (REVAS) from the Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine (SEMI) (2017) Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine (Baltimore) 96:e6083CrossRefGoogle Scholar
  28. 28.
    Murosaki T, Sato T, Akiyama Y, Nagatani K, Minota S (2017) Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Mod Rheumatol 27:95–101CrossRefGoogle Scholar
  29. 29.
    Yoo J, Kim HJ, Ahn SS, Jung SM, Song JJ, Park YB, Lee SW (2017) Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA negative vasculitis. Clin Exp Rheumatol 35(Suppl 103):111–118Google Scholar
  30. 30.
    Mohammad AJ, Mortensen KH, Babar J, Smith R, Jones RB, Nakagomi D, Sivasothy P, Jayne DRW (2017) Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: the influence of ANCA subtype. J Rheumatol 44:1458–1467CrossRefGoogle Scholar
  31. 31.
    Mohammad AJ, Segelmark MA (2014) Population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol 41:1366–1373CrossRefGoogle Scholar
  32. 32.
    West S, Arulkumaran N, Ind PW, Pusey CD (2013) Diffuse alveolar haemorrhage in ANCA-associated vasculitis. Intern Med 52:5–13CrossRefGoogle Scholar
  33. 33.
    Mahr A, Katsahian S, Varet H, Guillevin L, Hagen EC, Höglund P, Merkel PA, Pagnoux C, Rasmussen N, Westman K, Jayne DR, French Vasculitis Study Group (FVSG) and the European Vasculitis Society (EUVAS) (2013) Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody associated vasculitis: a cluster analysis. Ann Rheum Dis 72:1003–1010CrossRefGoogle Scholar
  34. 34.
    Chen KR (2013) Skin involvement in ANCA-associated vasculitis. Clin Exp Nephrol 17:676–682CrossRefGoogle Scholar
  35. 35.
    Suppiah R, Hadden RD, Batra R, Arden NK, Collins MP, Guillevin L, Jayne DR, Luqmani RA, European Vasculitis Study Group (2011) Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European vasculitis study group trials. Rheumatology (Oxford) 50:2214–2222CrossRefGoogle Scholar
  36. 36.
    Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC, European Vasculitis Study Group (EUVAS) (2002) Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 61:80–89CrossRefGoogle Scholar
  37. 37.
    Li ZY, Chang DY, Zhao MH, Chen M (2014) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol 66:1920–1926CrossRefGoogle Scholar
  38. 38.
    Walsh M, Flossmann O, Berden A, Westman K, Höglund P, Stegeman C, Jayne D, European Vasculitis Study Group (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542–548CrossRefGoogle Scholar
  39. 39.
    Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ (2012) Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64:3452–3462CrossRefGoogle Scholar
  40. 40.
    Córdova-Sánchez BM, Mejía-Vilet JM, Morales-Buenrostro LE, Loyola-Rodríguez G, Uribe-Uribe NO, Correa-Rotter R (2016) Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. Clin Rheumatol 35:1805–1816CrossRefGoogle Scholar
  41. 41.
    Kapitsinou PP, Ioannidis JP, Boletis JN, Sotsiou F, Nakopoulou L, Daphnis E, Moutsopoulos HM (2003) Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis. Am J Kidney Dis 41:29–37CrossRefGoogle Scholar
  42. 42.
    Sriskandarajah S, Aasarød K, Skrede S, Knoop T, Reisæter A, Bjørneklett R (2015) Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies. Nephrol Dial Transplant 30:i67–i75Google Scholar
  43. 43.
    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  • Yan Hong
    • 1
    • 2
  • Pengxian Shi
    • 1
  • Xia Liu
    • 3
  • Liu Yang
    • 3
  • Kang Li
    • 3
  • Feng Xu
    • 3
  • Shaoshan Liang
    • 3
  • Zhengzhao Liu
    • 3
  • Haitao Zhang
    • 3
  • Yinghua Chen
    • 3
    Email author
  • Weixin Hu
    • 1
    • 3
    Email author
  1. 1.Jinling Clinical Medical College of Nanjing Medical UniversityNanjingChina
  2. 2.The Affiliated Wuxi No. 2 People’s Hospital of Nanjing Medical UniversityWuxiChina
  3. 3.National Clinical Research Centre of Kidney Diseases, Nanjing Jinling HospitalNanjing University School of MedicineNanjingChina

Personalised recommendations